PatientsVille.com Logo

SYNCOPE and Gabapentin

PatientsVille

SYNCOPE Symptoms and Causes

Fainting is a temporary loss of consciousness. If you're about to faint, you'll feel dizzy, lightheaded, or nauseous. Your field of vision may "white out" or "black out." Your skin may be cold and clammy. You lose muscle control at the same time, and may fall down.

Fainting usually happens when your blood pressure drops suddenly, causing a decrease in blood flow to your brain. It is more common in older people. Some causes of fainting include

  • Heat or dehydration
  • Emotional distress
  • Standing up too quickly
  • Certain medicines
  • Drop in blood sugar
  • Heart problems

When someone faints, make sure that the airway is clear and check for breathing. The person should stay lying down for 10-15 minutes. Most people recover completely. Fainting is usually nothing to worry about, but it can sometimes be a sign of a serious problem. If you faint, it's important to see your health care provider and find out why it happened.

Check out the latest treatments for SYNCOPE

SYNCOPE treatment research studies

Gabapentin clinical trials, surveys and public health registries


Find Drug Side Effect reports



Gabapentin Side Effects

Completed Suicide (332)
Dizziness (329)
Somnolence (304)
Pain (286)
Headache (273)
Confusional State (257)
Nausea (248)
Off Label Use (227)
Tremor (215)
Depression (214)
Fatigue (213)
Fall (194)
Convulsion (184)
Feeling Abnormal (183)
Toxicity To Various Agents (176)
Suicidal Ideation (166)
Malaise (165)
Respiratory Arrest (163)
Cardiac Arrest (145)
Condition Aggravated (144)
Dyspnoea (113)
Pain In Extremity (112)
Myoclonus (108)
Anxiety (108)
Asthenia (107)
Amnesia (104)
Diarrhoea (102)
Insomnia (97)
Vision Blurred (90)
Gait Disturbance (85)
Vomiting (84)
Death (84)
Oedema Peripheral (83)
Disorientation (82)
Back Pain (80)
Rash (80)
Weight Increased (79)
Agitation (78)
Paraesthesia (74)
Memory Impairment (73)
Dyskinesia (73)
Abdominal Pain (73)
Hallucination (72)
Muscular Weakness (71)
Sedation (71)
Myalgia (70)
Loss Of Consciousness (70)
Renal Failure Acute (69)
Hypoaesthesia (66)
Muscle Spasms (66)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

Be careful! Avoid Gabapentin at all costs! My mother's doctor ordered a 900 mg/day dose. In the 2 years she was under this dose, she fell 5 times! No doctor 'suspected' this drug! Then, he increased the dose to...1800 mg/day! I almost lost her! I am

Dose Gabapantin have any ting to do with the nearves in your body

For the last two weeks I have been taking a lowish dose of Gabapentin for night-time nerve pain (100gm three times a day and then 200mg at night.) It has worked brilliantly for the pain and I was ecstatic BUT I have now wet the bed two nights in a r

GABAPENTIN noticed that medication got worsen n Nurgloist n don't listin. My problem n even rash n stomach ach n was getting stress out n decided go different doctor n was. Going take that chance with my n stop going to Nurgloist n been two.n bo

Great so far for my anxiety... just side effects has ... sexually saticfied,nausea little bit.. dizzynezz! lolz.. but great medication/ i think..

Having racing thoughts and unmotivated *DONT_KNOW*

Hear voices

Hello, I've been taking a cocktail of meds for 9 years to help treat acute nerve pain from a severe Brachial Plexus nerve avulsion C 7, 8, T1 and Spinal cord injury. Medications: Gabapentin 3600 mg., Methadone 100 mg. , Baclofen 20 mg. every 8 hour

I am having trouble falling to sleep, and I feel like I' having anxiety attacks I stopped the 400 Mg and I am taking 2 100 MGS now. I am doing this on my own , until I see my Dr next week. .

I am just starting Gabapentin to help with phantom pain from a BKA (below-knee-amputation). I am taking 600 mg and am scheduled to increase to 900 mg, then review results with my doctors. One of the side effects I seem to have is

Had syncope.ONCE, AFTER6 MONTHS,AFTER 1 MONTH

I took Noten in small amounts because of episodes of syncope and dizziness and an erratic heart beat. My cardiologist prescribed them after a positive tilt table test. I took one half of the prescribed dose and felt fantastic having more strength and

Inadequate control of blood sugar, have to starve myself to get lower blood sugar even on two types of insulin, diarrhoea, dizziness, syncope, dyspnoea, severe malaise, nausea, tremors.

My son, 15 years old, diagnosed as syncope, was prescribed 'SELOKEN XL(25mg). After learning that SELOKEN has side effect, I am scared to administer SELOKEN. What should I do?

Yesterday I had my menstrual period, and I take Midol, I was taken to the hospital, cause i feel Syncope, hiperventilation, dizzy. I think was the side effects, but the doctor tell me was a panic attack. I don't think so. cause I never experience som

SYNCOPE Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Unknown  Eastbourne Syncope Assessment Study II
Condition: Syncope
Interventions: Device: Sleuth Implantable Loop Recorder;   Other: Other
Outcome Measures: Primary Outcome 1. Time to ECG (objective) diagnosis of Syncope;   1. Time to ECG directed therapy. 2. Time to introduction of empiric therapy. 3. Time to first post induction Syncope. 4. Cost effectiveness analysis.
2 Recruiting Assessment of Midodrine in the Prevention of Vasovagal Syncope: The Prevention of Syncope Trial IV
Condition: Vasovagal Syncope
Interventions: Drug: midodrine hydrochloride;   Drug: matching placebo
Outcome Measures: The primary outcome measure will be the proportion of patients having at least one Syncope recurrence.;   A secondary outcome will be the time between the first and second Syncope recurrences.;   A secondary outcome will be the frequency of syncopal spells.;   A secondary outcome is the number, duration, and severity of presyncopal spells (as measured with the Calgary PreSyncope Scale(19)).;   A secondary outcomes will be quality of life as measured by the EQ-5D and the ISQL.
3 Not yet recruiting Assessment of Metoprolol in the Prevention of Vasovagal Syncope in Aging Subjects
Condition: Vasovagal Syncope
Interventions: Drug: Metoprolol;   Drug: Matching Placebo
Outcome Measures: The primary outcome measure will be the proportion of patients having at least one Syncope recurrence.;   A secondary outcome will be the time between the first and second Syncope recurrences.;   A secondary outcome will be the frequency of syncopal spells.;   A secondary outcome is the number, duration, and severity of presyncopal spells (as measured with the Calgary PreSyncope Scale);   A secondary outcomes will be quality of life as measured by the EQ-5D and the ISQL.
4 Recruiting Cardioneuroablation for Neurocardiogenic Syncope
Conditions: Neurocardiogenic Syncope;   Vasovagal Syncope
Interventions: Procedure: Cardioneuroablation;   Device: Biosense Webster Navistar ThermoCool Diagnostic/Ablation Deflectable Tip Catheter
Outcome Measures: Recurrence of Syncope;   Incidence of Serious Adverse Events
5 Recruiting Guideline-based Pacing Therapy for Reflex Syncope
Condition: Syncope
Intervention:
Outcome Measures: Syncope recurrence after PM implantation;   Syncope burden after PM implantation
6 Recruiting Stop Vasodepressor Drugs in Reflex Syncope
Condition: Hypotensive Syncope
Interventions: Drug: Vasoactive drug therapies;   Other: Stop/reduce vasoactive drugs
Outcome Measures: Recurrence of Syncope or preSyncope and adverse events;   Syncope;   PreSyncope
7 Recruiting Influence of Yoga in Patients With Neurocardiogenic Syncope
Condition: Syncope, Vasovagal
Intervention: Other: Yoga
Outcome Measures: Change in frequency of recurrent syncopal spells in patients with Neurocardiogenic Syncope (NCS);   Change in Heart Health
8 Recruiting Prevalence of Pulmonary Embolism in Patients With Syncope
Conditions: Syncope;   Pulmonary Embolism
Intervention: Other: Lung CT or V/Q scanning in patients with a high pre-test clinical probability of PE and/or a positive D-dimer
Outcome Measures: To assess the prevalence of PE in a large series of consecutive patients presenting with the first episode of Syncope;   To assess the prevalence of pulmonary embolism in patients with apparently unexplained Syncope
9 Recruiting Syncope: Pacing or Recording in the Later Years
Conditions: Syncope;   Heart Block;   Conduction Disorder of the Heart
Interventions: Procedure: pacemaker;   Procedure: implantable loop recorder
Outcome Measures: The primary outcome measure will be a composite of Major Adverse Study-Related Events (MASRE) in a 2-year observation period.;   Secondary outcome measures will include total number of syncopal spells.;   Secondary outcome measures will include the likelihood of a first recurrence of Syncope.;   Secondary outcome measures will include the physical trauma due to Syncope.;   Secondary outcome measures will include quality of life of the participants.
10 Not yet recruiting Syncope Prediction Study
Condition: Vasovagal Syncope
Intervention:
Outcome Measure: Number of participants with Syncope recurrence predicted by VVS prediction algorithm
11 Recruiting Improving Syncope Risk Stratification in Older Adults
Condition: Syncope
Intervention:
Outcome Measure: Combined death and serious cardiac events
12 Recruiting BAsel Syncope EvaLuation (BASEL IX) Study
Condition: Syncope
Intervention:
Outcome Measure: diagnostic and prognostic value of various novel and established biomarkers, clinical assessment and detailed patient history
13 Unknown  Optimizing Diagnostics Of Syncope Events Using Intelligent Telemetric Solutions.
Conditions: Cardiac Arrhythmia;   Cardiogenic Syncope
Interventions: Device: repeated 24 hours ECG Holter monitoring;   Device: Telemetric ECG monitoring
Outcome Measures: Recording of symptomatic or life threatening arrhythmia event;   Occurrence of silent (asymptomatic) arrhythmia event;   1. Verification of patient self assessment based on the Quality of Life questionnaire and EHRA scale against evidence of cardiac arrhythmia occurrence
14 Recruiting Efficacy of Transcatheter Ablation Using Anatomic Approach of Ganglionated Plexi Located in the Right Atrium to Prevent Neuromediated Cardioinhibitory Syncope
Condition: Neuromediated Cardioinhibitory Syncope
Intervention: Procedure: transcatheter ablation of ganglionated plexi in right atrium
Outcome Measure: neuromediated cardioinhibitory Syncope recurrence
15 Recruiting Mechanisms of Vasovagal Syncope
Conditions: Vasovagal Syncope;   Postural Tachycardia Syndrome
Interventions: Drug: Phenylephrine;   Drug: L-Ng-monomethyl Arginine (L-NMMA)
Outcome Measures: Heart rate and blood pressure in response to Lower Body Negative Pressure(LBNP);   Adrenergic neurotransmission as measured by Muscle Sympathetic Nerve Activity(MSNA), doppler ultrasound blood flow, venous Norepinephrine in response to Phenylephrine infusion
16 Recruiting Point-of-Care Ultrasound in the Emergency Department Evaluation of Syncope
Condition: Syncope
Intervention: Other: Point-of-Care Ultrasound
Outcome Measures: Time to Final Emergency Department Disposition;   Time to therapeutic intervention;   Time to clinical procedure;   Number and Type of other imaging studies;   Information Content provided by Point-of-Care Ultrasound;   Number and type of laboratory studies;   Number of and time to consultant services
17 Unknown  Adenosine Testing to DEtermine the Need for Pacing Therapy
Condition: Syncope
Interventions: Device: Pacemaker implantation (Medtronic);   Device: Implantable Loop Recorder (Medtronic)
Outcome Measures: Syncope Burden;   Time to first Syncope;   Number of patients with recurrent Syncope;   Quality of life;   Health economic analysis;   ECG diagnosis on ILR following syncopal episode in adenosine negative group
18 Recruiting Evaluation of the Efficiency of Hydration by Isotonic Solution in the Prevent of the Fainting Whole Blood Donors
Conditions: Fainting;   PreSyncope;   Syncopal Episode
Interventions: Other: tensing exercises;   Other: No tensing exercises
Outcome Measures: Accumulated incidence of presyncopal and syncopal reactions during blood donation, while still at the blood donation whole and within 48 hours of the blood donation, that required the donor to be placed in a 'Trendelenburg' position;   daily activities;   presyncopal and syncopal reactions of all donors;   presyncopal and syncopal reactions in the population of young donors (in schools);   presyncopal or syncopal reactions influence on subsequent blood donation;   Recurrence of presyncopal or syncopal reactions;   Explanatory variables of presyncopal and syncopal reactions;   subgroup analysis on collection unit characteristics;   medium term impact of the donation;   Restless legs syndrome
19 Unknown  Validation of a Non Invasive Blood Marker of SIDS and Vagal Disorders
Condition: Vagal Syncope
Interventions: Biological: Blood sampling;   Other: ECG-Holter 24 h tape and sino-carotid stimulation test
Outcome Measure:
20 Recruiting Essential Hypotension and Adaptability Registry
Conditions: Blood Pressure;   Depression;   Panic Attack;   Fibromyalgia;   POTS;   Inappropriate Sinus Tachycardia;   Coronary Heart Disease;   Acute Coronary Syndrome (ACS);   Acute Myocardial Infarction (AMI);   Cerebrovascular Disease (CVD);   Transient Ischemic Attack (TIA);   Atrial Fibrillation;   Diabetes Mellitus;   Cancer;   Systolic Heart Failure;   Diastolic Heart Failure;   Chronic Fatigue Syndrome;   Syncope;   Vasovagal Syncope
Intervention:
Outcome Measures: Relationship between Blood pressure group and comorbidities;   Relationship between adaptability group and comorbidities;   Relationship between blood pressure group, adaptability group and comorbidities;   Relationship between blood pressure group, habits and anthropometric, metabolic, endocrine, Electrocardiogram, Holter, ambulatory blood pressure monitoring (ABPM);   Relationship between blood pressure group, adaptability group, habits anthropometric, metabolic, endocrine, electrocardiographic, Holter, ambulatory arterial blood pressure monitoring.;   For metabolic disorders what it matters the most: the anthropometric variables vs blood pressure group vs adaptability group;   Relationship between adaptability group, habits and anthropometric, metabolic, endocrine, Electrocardiogram, Holter, ambulatory blood pressure monitoring (ABPM)